Utility of Soluble CD163 in the Clinical Management of Patients With Kawasaki Disease

• Egile Nagusiak: Yoshihiro Azuma (Egilea), Yasuo Suzuki (Egilea), Seigo Okada (Egilea), Chie Matsuguma (Egilea), Hiroyuki Wakiguchi (Egilea), Yuji Ohnishi (Egilea), Takashi Furuta (Egilea), Akiko Miyake (Egilea), Hiroki Yasudo (Egilea), Kiyoshi Ichihara (Egilea), Shouichi Ohga (Egilea), Shunji Hasegawa (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2020-04-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Objective: Intravenous immunoglobulin (IVIG) therapy is a useful first-line treatment for Kawasaki disease (KD); however, 10-20% of patients fail to respond and require additional IVIG. Soluble CD163 (sCD163) is considered a biomarker for macrophage activation. There are no reports measuring serum s...